NYSE · CIK 0000728387
CATX Perspective Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 35 d ago. Close $2.52 on Oct 12, 2026, +23% from the 52-week low and -55% from the high.
In brief
Perspective Therapeutics, Inc. (CATX) has 34 SEC Form 4 filings on file from 12 insiders, the latest filed on Sep 8, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 5 open-market sells worth $1.6M, net -$1.6M.
17 open-market trades have been scored at CATX. The newest: Lantheus Alpha Therapy, LLC (10% owner) sold $777k of stock on Sep 3, 2026, filed Sep 8, 2026, scored 42 (moderate). 2 insiders sold within 14 days of each other around Sep 3, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Perspective Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Lantheus Alpha Therapy, LLC owner sell | $777k 247,932 shares | -2% | - | |
| 35Weak | Lantheus Alpha Therapy, LLC owner sell | $357k 113,914 shares | -1% | - | |
| 31Weak | Lantheus Alpha Therapy, LLC owner sell | $131k 42,129 shares | -0% | - | |
| 30Weak | Lantheus Holdings, Inc. owner sell | $112k 35,769 shares | -0% | - | |
| 33Weak | Lantheus Holdings, Inc. owner sell | $246k 78,145 shares | -1% | - | |
| 37Weak | Jonathan Robert Hunt Chief Accounting Officer buy | $22k 11,000 shares | +23% | +21% from low-79% from high | |
| 41Moderate | Robert F Williamson III director buy | $20k 9,498 shares | +2595% | +24% from low-80% from high | |
| 73Notable | Juan Graham Chief Financial Officer buy | $75k 33,333 shares | +1649% | 0% from low-86% from high | |
| 58Moderate | Lori A Woods director buy | $50k 23,475 shares | +15% | 0% from low-87% from high | |
| 69Notable | Robert F Williamson III director buy | $132k 60,337 shares | +124% | 0% from low-86% from high | |
| 75Notable | Johan M. Spoor Chief Executive Officer buy | $60k 26,676 shares | +71% | 0% from low-86% from high | |
| 48Moderate | Heidi Henson director buy | $100k 25,975 shares | - | - | |
| 56Moderate | Johan M. Spoor CEO buy | $30k 8,000 shares | +28% | - | |
| 50Moderate | Jonathan Robert Hunt Chief Financial Officer buy | $49k 12,829 shares | +36% | - | |
| 30Weak | Robert F Williamson III director buy | $23k 6,266 shares | +1% | - | |
| 53Moderate | Johan M. Spoor CEO buy | $100k 26,500 shares | +19% | - | |
| 45Moderate | Jonathan Robert Hunt Chief Financial Officer buy | $32k 125,000 shares | +65% | +24% from low-64% from high |
Transactions
Every row filed, 42 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Lantheus Alpha Therapy, LLC owner | SOpen-market sale Common Stock | -80,783 | $3.11 | $251k | 11,440,513 | 35 d ago |
| Sep 4, 2026 | Lantheus Alpha Therapy, LLC owner | SOpen-market sale Common Stock | -167,149 | $3.15 | $526k | 11,273,364 | 35 d ago |
| Aug 31, 2026 | Lantheus Alpha Therapy, LLC owner | SOpen-market sale Common Stock | -78,145 | $3.14 | $246k | 11,599,194 | 39 d ago |
| Sep 2, 2026 | Lantheus Alpha Therapy, LLC owner | SOpen-market sale Common Stock | -42,129 | $3.11 | $131k | 11,521,296 | 39 d ago |
| Sep 1, 2026 | Lantheus Alpha Therapy, LLC owner | SOpen-market sale Common Stock | -35,769 | $3.12 | $112k | 11,563,425 | 39 d ago |
| Sep 1, 2026 | Lantheus Holdings, Inc. owner | SOpen-market sale Common Stock | -35,769 | $3.12 | $112k | 11,563,425 | 40 d ago |
| Aug 31, 2026 | Lantheus Holdings, Inc. owner | SOpen-market sale Common Stock | -78,145 | $3.14 | $246k | 11,599,194 | 41 d ago |
| Mar 2, 2026 | Robert F Williamson III director | AGrant or award Stock option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 4, 2026 |
| Mar 2, 2026 | Markus Puhlmann Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Mar 4, 2026 |
| Mar 2, 2026 | Johan M. Spoor Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +735,000 | $0.00 | $0 | 735,000 | Mar 4, 2026 |
| Mar 2, 2026 | Lori A Woods director | AGrant or award Stock option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 4, 2026 |
| Mar 2, 2026 | Frank Morich director | AGrant or award Stock option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 4, 2026 |
| Mar 2, 2026 | Maria E Martinez director | AGrant or award Stock option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 4, 2026 |
| Mar 2, 2026 | Jonathan Robert Hunt Chief Accounting Officer | AGrant or award Stock option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Mar 4, 2026 |
| Mar 2, 2026 | Heidi Henson director | AGrant or award Stock option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 4, 2026 |
| Nov 13, 2025 | Jonathan Robert Hunt Chief Accounting Officer | POpen-market purchase Common Stock | +11,000 | $2.03 | $22k | 59,800 | Nov 17, 2025 |
| Nov 12, 2025 | Robert F Williamson III director | POpen-market purchase Common Stockindirect: RFW3 Revocable Trust | +9,498 | $2.10 | $20k | 9,864 | Nov 14, 2025 |
| Sep 4, 2025 | Joel Sendek Chief Financial Officer | AGrant or award Stock option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Sep 5, 2025 |
| Sep 3, 2025 | Maria E Martinez director | AGrant or award Stock option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Sep 5, 2025 |
| Mar 28, 2025 | Johan M. Spoor Chief Executive Officer | POpen-market purchase Common Stock | +22,026 | $2.24 | $49k | 59,383 | Apr 1, 2025 |
| Mar 28, 2025 | Robert F Williamson III director | POpen-market purchase Common Stock | +22,192 | $2.27 | $50k | 70,837 | Apr 1, 2025 |
| Mar 28, 2025 | Juan Graham Chief Financial Officer | POpen-market purchase Common Stock | +33,333 | $2.25 | $75k | 35,354 | Apr 1, 2025 |
| Mar 31, 2025 | Lori A Woods director | POpen-market purchase Common Stockindirect: By Woods Family Living Trust | +23,475 | $2.13 | $50k | 183,460 | Apr 1, 2025 |
| Mar 28, 2025 | Johan M. Spoor Chief Executive Officer | POpen-market purchase Common Stockindirect: By Child #1 | +4,650 | $2.21 | $10k | 4,650 | Apr 1, 2025 |
| Mar 31, 2025 | Robert F Williamson III director | POpen-market purchase Common Stock | +38,145 | $2.14 | $82k | 108,982 | Apr 1, 2025 |
| Mar 3, 2025 | Heidi Henson director | AGrant or award Stock option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 5, 2025 |
| Mar 3, 2025 | Jonathan Robert Hunt Chief Accounting Officer | AGrant or award Stock option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Mar 5, 2025 |
| Jan 6, 2025 | Juan Graham Chief Financial Officer | AGrant or award Stock option (right to buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jan 7, 2025 |
| Dec 4, 2024 | Heidi Henson director | POpen-market purchase Common Stockindirect: By Revocable Trust | +25,975 | $3.85 | $100k | 25,975 | Dec 6, 2024 |
| Dec 4, 2024 | Johan M. Spoor CEO | POpen-market purchase Common Stock | +8,000 | $3.77 | $30k | 36,257 | Dec 4, 2024 |
| Nov 25, 2024 | Jonathan Robert Hunt Chief Financial Officer | POpen-market purchase Common Stock | +400 | $3.55 | $1,420 | 36,371 | Nov 27, 2024 |
| Nov 25, 2024 | Robert F Williamson III director | POpen-market purchase Common Stock | +3,647 | $3.62 | $13k | 427,439 | Nov 27, 2024 |
| Nov 25, 2024 | Jonathan Robert Hunt Chief Financial Officer | POpen-market purchase Common Stock | +29 | $3.94 | $114 | 36,400 | Nov 27, 2024 |
| Nov 25, 2024 | Robert F Williamson III director | POpen-market purchase Common Stock | +2,619 | $3.67 | $9,612 | 430,058 | Nov 27, 2024 |
| Nov 25, 2024 | Jonathan Robert Hunt Chief Financial Officer | POpen-market purchase Common Stock | +2,400 | $3.60 | $8,640 | 38,800 | Nov 27, 2024 |
| Nov 25, 2024 | Jonathan Robert Hunt Chief Financial Officer | POpen-market purchase Common Stock | +10,000 | $3.88 | $39k | 48,800 | Nov 27, 2024 |
| Nov 25, 2024 | Johan M. Spoor CEO | POpen-market purchase Common Stock | +14,500 | $3.78 | $55k | 152,072 | Nov 26, 2024 |
| Nov 25, 2024 | Johan M. Spoor CEO | POpen-market purchase Common Stockindirect: By IRA of Reporting Owner | +5,400 | $3.80 | $21k | 5,400 | Nov 26, 2024 |
| Nov 25, 2024 | Johan M. Spoor CEO | POpen-market purchase Common Stockindirect: By IRA of Spouse | +6,600 | $3.80 | $25k | 66,600 | Nov 26, 2024 |
| Dec 18, 2023 | Jonathan Robert Hunt Chief Financial Officer | POpen-market purchase Common Stock | +125,000 | $0.26 | $32k | 316,710 | Dec 19, 2023 |
| Dec 12, 2023 | Heidi Henson director | AGrant or award Stock Options (right to buy)derivative | +230,000 | $0.00 | $0 | 930,000 | Dec 14, 2023 |
| Dec 12, 2023 | Jonathan Robert Hunt Chief Financial Officer | AGrant or award Stock Options (right to buy)derivative | +1,248,776 | $0.00 | $0 | 2,527,429 | Dec 14, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Juan GrahamChief Financial Officer
- Heidi Hensondirector
- Jonathan Robert HuntChief Financial Officer
- Lantheus Alpha Therapy, LLCowner
- Lantheus Holdings, Inc.owner
- Maria E Martinezdirector
- Frank Morichdirector
- Markus PuhlmannChief Medical Officer
- Joel SendekChief Financial Officer
- Johan M. SpoorChief Executive Officer
- Robert F Williamson IIIdirector
- Lori A Woodsdirector
Questions about CATX
Answered from the filings on this page, as of the latest one.
Are insiders buying CATX?
As of Sep 8, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 5 open-market sells worth $1.6M by 2 insiders at Perspective Therapeutics, Inc. in the last 90 days, net -$1.6M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade CATX on the open market?
Lantheus Alpha Therapy, LLC (10% owner) sold $777k of CATX on Sep 3, 2026 and filed the Form 4 on Sep 8, 2026. InsiderTell scored 42 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Perspective Therapeutics, Inc.?
12 people have filed a Form 4 at Perspective Therapeutics, Inc., among them Juan Graham (Chief Financial Officer), Heidi Henson (director), Jonathan Robert Hunt (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.